A case of familial progressive hyperpigmentation with or without hypopigmentation presenting with hypopigmented striae along the lines of Blaschko.

hyperpigmentation loss of heterozygosity mosaicism pigmentation disorders stem cell factor

Journal

The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545

Informations de publication

Date de publication:
13 Sep 2024
Historique:
revised: 23 08 2024
received: 17 05 2024
accepted: 26 08 2024
medline: 13 9 2024
pubmed: 13 9 2024
entrez: 13 9 2024
Statut: aheadofprint

Résumé

Familial progressive hyperpigmentation with or without hypopigmentation (FPHH) is an autosomal dominant disorder characterized by widespread skin hyperpigmentation, café-au-lait spots, and hypopigmented circular macules, resulting from KITLG variants. KITLG, expressed by keratinocytes, binds to KIT on melanocytes, stimulating melanogenesis. Disturbances in the KITLG-KIT interaction result in diffuse hyperpigmentation in FPHH. However, the mechanisms behind hypopigmented macule formation remain unclear. This report presents a unique FPHH case in a patient with a novel KITLG mutation (Ser78Leu). Notably, the patient showed multiple hypopigmented macules and striae along the lines of Blaschko. Digital polymerase chain reaction analysis of the DNA from skin and blood tissues indicated a copy-neutral loss of heterozygosity at the KITLG locus, only in the hypopigmented macule. These findings suggest that the hypopigmented macules might result from revertant mosaicism. Conversely, café-au-lait spots do not follow the lines of Blaschko and can superimpose on the hypopigmented striae, indicating a distinct pathogenesis. This case contributes to the understanding of the genetic mechanisms in FPHH.

Identifiants

pubmed: 39269165
doi: 10.1111/1346-8138.17459
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 Japanese Dermatological Association.

Références

Amyere M, Vogt T, Hoo J, Brandrup F, Bygum A, Boon L, et al. KITLG mutations cause familial progressive hyper‐ and hypopigmentation. J Invest Dermatol. 2011;131:1234–1239.
Wang ZQ, Si L, Tang Q, Lin D, Fu Z, Zhang J, et al. Gain‐of‐function mutation of KIT ligand on melanin synthesis causes familial progressive hyperpigmentation. Am J Hum Genet. 2009;84:672–677.
Kunisada T, Lu SZ, Yoshida H, Nishikawa S, Nishikawa SI, Mizoguchi M, et al. Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med. 1998;187:1565–1573.
Gorenjak M, Fijačko N, Bogomir Marko P, Živanović M, Potočnik U. De novo mutation in KITLG gene causes a variant of familial progressive hyper‐ and hypo‐pigmentation (FPHH). Mol Genet Genomic Med. 2021;9:e1841.
Zhang J, Cheng R, Liang J, Ni C, Li M, Yao Z. Report of a child with sporadic familial progressive hyper‐ and hypopigmentation caused by a novel KITLG mutation. Br J Dermatol. 2016;175:1369–1371.
Clemmensen A, Thomassen M, Clemmensen O, Tan Q, Kruse TA, Petersen TK, et al. Extraction of high‐quality epidermal RNA after ammonium thiocyanate‐induced dermo‐epidermal separation of 4 mm human skin biopsies. Exp Dermatol. 2009;18:979–984.
Idogawa M, Hida T, Tanaka T, Ohira N, Tange S, Sasaki Y, et al. Renal angiomyolipoma (AML) harboring a missense mutation of TSC2 with copy‐neutral loss of heterozygosity (CN‐LOH). Cancer Biol Ther. 2020;21:315–319.
Multiple sequence alignment by CLUSTALW. Available from: https://www.genome.jp/tools‐bin/clustalw Accessed 01 May 2024.
Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell. 2007;130:323–334.
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF chimera–a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–1612.
Liu Z, Zhu Z, Luo J, Yang B. Familial progressive hyper‐ and hypopigmentation caused by a novel mutation in site II of the KITLG gene. J Dermatol. 2021;48:e462–e463.
Rabinovich E, Heyne M, Bakhman A, Kosloff M, Shifman JM, Papo N. Identifying residues that determine SCF molecular‐level interactions through a combination of experimental and in silico analyses. J Mol Biol. 2017;429:97–114.
Kubo A, Sasaki T, Suzuki H, Shiohama A, Aoki S, Sato S, et al. Clonal expansion of second‐hit cells with somatic recombinations or C>T transitions form porokeratosis in MVD or MVK mutant heterozygotes. J Invest Dermatol. 2019;139:2458–2466.
Welker P, Schadendorf D, Artuc M, Grabbe J, Henz BM. Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. Br J Cancer. 2000;82:1453–1458.
Sorlin A, Maruani A, Aubriot‐Lorton MH, Kuentz P, Duffourd Y, Teysseire S, et al. Mosaicism for a KITLG mutation in linear and whorled nevoid hypermelanosis. J Invest Dermatol. 2017;137:1575–1578.

Auteurs

Tokimasa Hida (T)

Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Masashi Idogawa (M)

Department of Medical Genome Sciences, Cancer Research Institute, Sapporo Medical University School of Medicine, Sapporo, Japan.

Aki Ishikawa (A)

Department of Medical Genetics, Sapporo Medical University School of Medicine, Sapporo, Japan.

Masae Okura (M)

Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Satoru Sasaki (S)

Center for Vascular Anomalies, Department of Plastic and Reconstructive Surgery, Tonan Hospital, Sapporo, Japan.

Takashi Tokino (T)

Department of Medical Genome Sciences, Cancer Research Institute, Sapporo Medical University School of Medicine, Sapporo, Japan.

Hisashi Uhara (H)

Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Classifications MeSH